|
시장보고서
상품코드
2087698
수술용 스테이플러 시장 : 디바이스 유형별, 자동화 레벨, 제품 유형, 소재, 용도, 최종사용자별 - 시장 예측(2026-2032년)Surgical Stapling Devices Market by Device Type, Automation, Product Type, Material, Application, End User - Global Forecast 2026-2032 |
||||||
360iResearch
수술용 스테이플러 시장은 2032년까지 연평균 복합 성장률(CAGR) 8.95%로 103억 9,000만 달러에 달할 것으로 예측됩니다.
| 주요 시장 통계 | |
|---|---|
| 기준 연도 : 2025년 | 57억 달러 |
| 추정 연도 : 2026년 | 61억 3,000만 달러 |
| 예측 연도 : 2032년 | 103억 9,000만 달러 |
| CAGR(%) | 8.95% |
수술용 스테이플러는 소화기외과, 흉부외과, 비만외과, 대장항문외과, 산부인과 및 일반외과 등 각 분야에서 널리 사용되고 있으며, 상처 봉합 및 문합에 필수적인 기구입니다. 이러한 수요는 전 세계적으로 최소 침습 수술로의 전환, 암 및 비만 관련 질환의 부담 증가, 그리고 수술 건수가 많은 수술실에서 일관된 조직 처리 방식의 필요성에 의해 뒷받침되고 있습니다.
수술용 스테이플러 시장의 양상은 최소 침습 수술, 로봇 보조 수술, 그리고 적응증 사례가 입원 시설에서 외래수술센터(ASC)로 이동하는 추세에 따라 재편되고 있습니다. 병원에서는 수술 절차를 단축하고, 예측 가능한 수술 진행을 지원하며, 수술팀 간의 편차를 줄여주는 기기를 우선적으로 도입하고 있습니다.
인공지능(AI)은 수술 전 계획, 수술 중 의사결정 지원, 로봇 기술, 품질 모니터링 및 시판 후 분석을 통해 수술용 스테이플러 분야에 영향을 미치기 시작하고 있습니다. AI를 활용한 영상 진단 및 워크플로우 도구는 스테이플러를 발사하기 전에 임상의가 해부학적 구조, 조직 관류 및 시술의 위험성을 평가하는 데 도움이 되지만, 최종적인 임상적 책임은 여전히 외과의사에게 있습니다.
북미는 미국과 캐나다에 걸쳐 광범위하게 구축된 최소 침습 수술 인프라, 강력한 보험 급여 제도, 확립된 외래수술센터(ASC) 네트워크, 그리고 엄격한 의료기기 감독 체제 덕분에, 첨단 수술용 스테이플러 기기의 도입률이 여전히 높은 지역입니다. 유럽에서는 국민건강보험 제도, 고령화, 암 및 대장 외과 수술에 대한 수요, 그리고 임상적 근거, 시판 후 임상 추적 관찰, 의료기기의 추적성을 중시하게 된 EU 의료기기 규정에 대한 준수가 뒷받침되면서 안정적인 수요가 나타나고 있습니다.
아세안 지역 수요는 의료 관광, 사립 병원의 확대, 그리고 외과 수술 접근성 개선을 위한 정부의 이니셔티브에 힘입어 증가하고 있으며, 싱가포르, 태국, 말레이시아, 인도네시아, 베트남, 필리핀에서는 보험 환급 제도, 외과 의사의 연수, 병원의 설비 투자 현황에 따라 도입 수준에 차이가 나타나고 있습니다. GCC 국가들에서는 병원 인프라에 대한 투자, 전문 의료 서비스 확충, 국가 의료 개혁 프로그램, 그리고 3차 의료기관 및 사립병원에서 국제적으로 인정받은 외과 기술을 선호하는 경향에 힘입어 도입이 가속화되고 있습니다.
미국에서는 수술 건수 증가, 복강경 및 로봇 수술 플랫폼의 광범위한 활용, 외래수술센터(ASC)의 확대, 그리고 유해 사건 보고 및 의료기기 고유 식별(UDI) 요건에 기반한 FDA의 엄격한 감독에 힘입어 수요가 뒷받침되고 있습니다. 캐나다에서는 품질, 주 정부의 조달, 비용 대비 효과가 중시되고 있습니다. 한편, 멕시코에서는 사립 병원의 성장, 의료 관광, 국경을 초월한 의료 활동이 수요를 견인하고 있습니다. 브라질은 인구 기준으로 라틴아메리카 최대의 외과 시장이며, 그 수요는 민간 보험의 보급률, 공공 부문의 예산 주기, 주요 대도시권에서의 전문 외과 수술 확대에 의해 형성되고 있습니다.
업계 리더는 비만 외과, 대장 외과, 흉부 외과, 산부인과 및 최소 침습 수술 용도에 최적화된 스테이플러를 포함하여, 제품 포트폴리오를 각 수술 방식에 따른 임상적 가치에 맞추어 조정해야 합니다. 증거를 도출할 때는 스테이플 라인의 완전성, 누출 감소, 지혈, 수술 효율, 조직 두께에 대한 성능, 그리고 수술팀 전체의 사용 편의성에 초점을 맞추어야 하며, 가능한 경우 실제 임상 데이터로 뒷받침되어야 합니다.
본 요약본은 규제 데이터베이스, 의료 시스템 통계, 동료 심사를 거친 외과 문헌, 안전성 관련 정보, 조달 동향, 그리고 WHO, OECD, FDA, 유로스타트, 각국 보건 기관 등의 조직이 제공하는 인구 통계 지표 등, 일반적으로 공개되고 기관에 의해 인정된 2차 정보를 바탕으로 한 체계화된 2차 조사 프레임워크를 활용하여 작성되었습니다.
수술용 스테이플러 시장은 범용 봉합 의료기기 범주에서 최소 침습 수술, 로봇 기술, AI를 활용한 워크플로우 인텔리전스, 그리고 더욱 엄격해진 가치 기반 조달에 의해 형성되는 임상적으로 차별화된 부문으로 진화하고 있습니다. 병원 측은 환자의 안전, 외과 의사의 업무 효율, 그리고 수술실의 효율성을 지원하면서 시술의 일관성을 높여줄 의료기기를 찾고 있습니다.
The Surgical Stapling Devices Market is projected to grow by USD 10.39 billion at a CAGR of 8.95% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 5.70 billion |
| Estimated Year [2026] | USD 6.13 billion |
| Forecast Year [2032] | USD 10.39 billion |
| CAGR (%) | 8.95% |
Surgical stapling devices are essential wound-closure and anastomosis tools used across gastrointestinal, thoracic, bariatric, colorectal, gynecologic, and general surgery. Demand is supported by the global shift toward minimally invasive surgery, the rising burden of cancer and obesity-related conditions, and the need for consistent tissue approximation in high-volume operating rooms.
The market includes manual, powered, disposable, and reusable staplers, along with reloads and specialty devices designed for varying tissue thicknesses. Procurement decisions increasingly depend on clinical reliability, staple-line security, ergonomic design, compatibility with laparoscopic and robotic workflows, and evidence demonstrating lower complication risk compared with inconsistent manual techniques in selected procedures.
The surgical stapling devices landscape is being reshaped by minimally invasive surgery, robotic-assisted procedures, and the movement of appropriate cases from inpatient settings to ambulatory surgical centers. Hospitals are prioritizing devices that shorten operative steps, support predictable firing, and reduce variation across surgical teams.
A second transformation is economic and regulatory. Health systems are scrutinizing premium-priced powered staplers and reload usage, while regulators continue to emphasize post-market surveillance, adverse event reporting, unique device identification, and device traceability. Manufacturers that combine clinical evidence, surgeon training, and supply resilience are better positioned as hospitals standardize vendor panels and evaluate total procedure value rather than unit price alone.
Artificial intelligence is beginning to influence surgical stapling through preoperative planning, intraoperative decision support, robotics, quality monitoring, and post-market analytics. AI-enabled imaging and workflow tools can help clinicians assess anatomy, tissue perfusion, and procedural risk before a stapler is fired, although final clinical responsibility remains with the surgeon.
Across the value chain, AI can improve demand planning for reloads, identify complaint patterns from service and adverse-event data, and support design validation by analyzing large volumes of bench, simulation, and clinical performance information. The cumulative impact is not a replacement for surgical judgment; it is a gradual improvement in consistency, training, traceability, and evidence generation for surgical stapling outcomes.
North America remains a high-adoption region for advanced surgical stapling devices because of extensive minimally invasive surgery infrastructure, strong reimbursement mechanisms, established ambulatory surgical center networks, and rigorous device oversight in the United States and Canada. Europe shows steady demand supported by universal health systems, aging populations, cancer and colorectal surgery needs, and compliance with the EU Medical Device Regulation, which has increased emphasis on clinical evidence, post-market clinical follow-up, and device traceability.
Asia-Pacific is expanding through rising surgical capacity, private hospital investment, and growth in bariatric, oncology, gastrointestinal, and thoracic procedures in China, India, Japan, South Korea, and Australia. Latin America is led by Brazil and Mexico, where private-sector procedure growth and public-hospital modernization create opportunities despite budget constraints and uneven reimbursement. The Middle East is investing in tertiary-care surgical centers, particularly in the Gulf, with demand tied to specialist surgery, medical tourism, and hospital accreditation initiatives. Africa's adoption is more selective and concentrated in urban referral hospitals, where access to trained surgeons, procurement budgets, maintenance capacity, and reliable supply chains are decisive for surgical stapling device utilization.
ASEAN demand is supported by medical tourism, expanding private hospitals, and government efforts to improve surgical access, with Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines showing different levels of adoption based on reimbursement, surgeon training, and hospital capital investment. GCC countries are accelerating uptake through hospital infrastructure investment, specialty-care expansion, national healthcare transformation programs, and a preference for internationally certified surgical technologies in tertiary and private hospitals.
The European Union is shaped by MDR compliance, tender-based procurement, value analysis committees, and strong evidence expectations, favoring suppliers with robust clinical documentation, vigilance processes, and traceability systems. BRICS countries offer scale through large surgical populations and expanding hospital networks, but pricing, local manufacturing policies, import controls, and public procurement requirements strongly influence access. G7 markets generally lead in premium stapling technologies, minimally invasive surgery adoption, and structured surgeon training, while NATO member countries overlap significantly with advanced European and North American health systems where supply security, regulatory alignment, and resilient procurement channels are increasingly important.
The United States anchors demand through high surgical volumes, broad use of laparoscopic and robotic platforms, ambulatory surgical center growth, and rigorous FDA oversight supported by adverse-event reporting and unique device identification requirements. Canada emphasizes quality, provincial procurement, and cost-effectiveness, while Mexico benefits from private hospital growth, medical tourism, and cross-border healthcare activity. Brazil is Latin America's largest surgical market by population, with demand shaped by private insurance penetration, public-sector budget cycles, and expanding specialist surgery in major urban centers.
In Europe, the United Kingdom, Germany, France, Italy, and Spain combine aging demographics with established surgical networks, oncology care pathways, and minimally invasive procedure adoption, although tendering, hospital value analysis, and EU MDR-linked evidence expectations affect brand selection. Russia's market is influenced by localization priorities, public procurement rules, and import dynamics. China is expanding through hospital modernization, domestic device competition, and rising minimally invasive surgery capacity; India is driven by rising procedure volumes, affordability needs, and private-sector hospital expansion; Japan prioritizes quality, precision, and aging-related surgery; Australia has strong adoption in specialist centers supported by established regulatory review; and South Korea benefits from advanced hospitals, robotic surgery penetration, and export-oriented medtech capabilities.
Industry leaders should align product portfolios with procedure-specific clinical value, including staplers optimized for bariatric, colorectal, thoracic, gynecologic, and minimally invasive applications. Evidence generation should focus on staple-line integrity, leak reduction, bleeding control, operative efficiency, tissue-thickness performance, and usability across surgical teams, supported by real-world data where available.
Commercial teams should pair device innovation with surgeon education, simulation-based training, and standardized firing protocols. Manufacturers should strengthen reload availability, dual-source critical components, sterile packaging controls, and regulatory documentation for FDA, EU MDR, and major Asia-Pacific requirements. Competitive advantage will come from combining clinical trust, economic proof, digital traceability, training depth, and supply reliability.
This executive summary is developed using a structured secondary-research framework based on publicly available and institutionally recognized sources, including regulatory databases, health-system statistics, peer-reviewed surgical literature, safety communications, procurement trends, and demographic indicators from organizations such as WHO, OECD, FDA, Eurostat, and national health agencies.
Insights are triangulated across clinical demand drivers, procedure trends, regulatory requirements, technology adoption, hospital investment, and regional healthcare infrastructure. The analysis avoids unverified market-size claims and prioritizes evidence-backed interpretation of how surgical volumes, minimally invasive procedures, reimbursement systems, value-based procurement, and device-safety expectations influence the surgical stapling devices market.
The surgical stapling devices market is advancing from a commodity closure category into a clinically differentiated segment shaped by minimally invasive surgery, robotics, AI-enabled workflow intelligence, and stricter value-based procurement. Hospitals are seeking devices that improve procedural consistency while supporting patient safety, surgeon ergonomics, and operating-room efficiency.
Manufacturers that deliver reliable firing performance, strong clinical evidence, training support, digital traceability, and region-specific access strategies will be best positioned. As regulatory scrutiny and cost pressure increase, success will depend on proving measurable value across surgeons, hospitals, payers, and patients without compromising safety, supply continuity, or procedural outcomes.